Buy Rating for Editas Medicine Driven by Strategic Focus on In Vivo CRISPR Gene Editing and Intellectual Property Catalysts

TIPRANKS11-06

Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Editas Medicine (EDIT – Research Report). The associated price target rem...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481625631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481625631","market":"us","top_or_hot":-1,"title":"Buy Rating for Editas Medicine Driven by Strategic Focus on In Vivo CRISPR Gene Editing and Intellectual Property Catalysts","media":"TIPRANKS","content":"<div>\n<p>Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Editas Medicine (EDIT – Research Report). The associated price target rem...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/buy-rating-for-editas-medicine-driven-by-strategic-focus-on-in-vivo-crispr-gene-editing-and-intellectual-property-catalysts?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy Rating for Editas Medicine Driven by Strategic Focus on In Vivo CRISPR Gene Editing and Intellectual Property Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy Rating for Editas Medicine Driven by Strategic Focus on In Vivo CRISPR Gene Editing and Intellectual Property Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 16:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/blurbs/buy-rating-for-editas-medicine-driven-by-strategic-focus-on-in-vivo-crispr-gene-editing-and-intellectual-property-catalysts?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Editas Medicine (EDIT – Research Report). The associated price target rem...</p>\n\n<a href=\"https://www.tipranks.com/news/blurbs/buy-rating-for-editas-medicine-driven-by-strategic-focus-on-in-vivo-crispr-gene-editing-and-intellectual-property-catalysts?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EDIT","symbol_name":"Editas Medicine, Inc.","start_time":0,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-editas-medicine-driven-by-strategic-focus-on-in-vivo-crispr-gene-editing-and-intellectual-property-catalysts?utm_source=itigerup.com&utm_medium=referral","article_id":"2481625631","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-editas-medicine-driven-by-strategic-focus-on-in-vivo-crispr-gene-editing-and-intellectual-property-catalysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2481625631","pubTimestamp":1730880971,"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Editas Medicine (EDIT – Research Report). The associated price target rem...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"EDIT":"Editas Medicine, Inc.","CRSP":"CRISPR Therapeutics AG"},"translate_title":"对体内CRISPR基因编辑和知识产权催化剂的战略关注推动了Editas Medicine的买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1,"EDIT":1},"content_text":"Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Editas Medicine (EDIT – Research Report). The associated price target rem...","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481625631"}